Search company, investor...

Kallyope

kallyope.com

Founded Year

2015

Stage

Series D | Alive

Total Raised

$479M

Last Raised

$236M | 10 mos ago

About Kallyope

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis. The company integrates technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology.

Headquarters Location

430 East 29th Street 10th Floor

New York, New York, 10016,

United States

646-475-4385

Missing: Kallyope's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kallyope's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Kallyope

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Kallyope in 4 CB Insights research briefs, most recently on Jan 31, 2022.

Expert Collections containing Kallyope

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kallyope is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,201 items

O

Omics

1,542 items

G

Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

B

Biopharma Tech

6,079 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kallyope Patents

Kallyope has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Gastrointestinal tract disorders
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/3/2022

11/29/2022

Gastrointestinal tract disorders, Inflammations, Cannabinoids, Autoimmune diseases, Diseases of intestines

Grant

Application Date

2/3/2022

Grant Date

11/29/2022

Title

Related Topics

Gastrointestinal tract disorders, Inflammations, Cannabinoids, Autoimmune diseases, Diseases of intestines

Status

Grant

Latest Kallyope News

Seattle startup with fresh approach to Parkinson’s and Alzheimer’s disease raises $96M

Nov 29, 2022

Microscopy image of neurons in the mouse brain. (Cajal Neuroscience Image) Cajal Neuroscience , a Seattle startup taking a unique approach to developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, revealed more details about its strategy and announced $96 million in funding Tuesday. Biopharma companies have spent  billions of dollars  over decades on failed trials for Alzheimer’s directed at just one target, amyloid-beta. The one drug available against that target, Biogen’s Aduhelm, was approved in the U.S. based on limited data and has not been commercially successful. There are numerous potential unexplored drug targets for neurodegenerative diseases, said Cajal CEO Ignacio Muñoz-Sanjuán in an interview with GeekWire. Large-scale human genetic studies have identified hundreds of genetic variants that affect the risk of developing such conditions. But how the genes involved affect cellular processes and disease is not fully known. Cajal was founded in 2020 to systematically collect such data to reveal key molecules involved in neurodegeneration, with an intitial focus on Alzheimer’s and Parkinson’s disease. By exploring a large range of potential drug targets, “the field is going back to the basics in some ways,” said Muñoz-Sanjuán. From left, Cajal CEO Ignacio Muñoz-Sanjuán and co-founders Ian Peikon, chief scientific officer, and Andrew Dervan, chief operating officer. (Cajal Neuroscience Photo) Other companies exploring fresh approaches to neurodegenerative disease include Seattle startup Athira Pharma. Athira’s compound designed to affect neuronal growth, however, has proven disappointing so far in phase 2 trials for Alzheimer’s disease, prompting a change in the design of the ongoing study. On Tuesday researchers are expecting full data from a phase 3 study of lecanemab, another Biogen and Esai experimental drug targeting amyloid-beta. The companies released preliminary data in September suggesting that lecanemab could ease cognitive decline, but more recently the agent has been linked to two deaths, according to reports in Science and STAT . Yet another amyloid-beta targeting experimental drug, developed by Roche, failed to show benefit in two large trials this month. Late stage trials of experimental drugs for Parkinson’s disease have similarly failed to yield new treatment options. Muñoz-Sanjuán was previously vice president of translational biology at the Cure Huntington’s Disease Initiative (CHDI) Foundation and took the helm of Cajal earlier this month. Earlier, two co-founders helped build up the company: chief operating officer Andrew Dervan , who previously led cell therapy business development at Bristol Myers Squibb, and chief scientific officer Ian Peikon , previously director of platform biology and technology at Kallyope, a New York City biotech startup. Board members also helped build Cajal, including chair and co-founder Robert Hershberg , a venture partner at Frazier Life Sciences and former Celgene executive. The company now has 56 employees. Building the company in Seattle When Peikon left Kallyope in 2019 he was tapped to become an entrepreneur-in-residence at New York City-based Lux Capital, which led the new Series A funding round for Cajal, along with The Column Group. Lux Capital and The Column Group were also both investors in Kallyope . Peikon helped pull together three scientific co-founders to form Cajal: Cold Spring Harbor Laboratory professor Anthony Zador ; Baylor College of Medicine professor Huda Zoghbi , a science partner at The Column Group; and Columbia professor Charles Zuker , a Kalyope co-founder who is also a science partner at The Column Group. Together, they conceived of a pipeline to identify and systematically assess new drug targets. “The three of them put their heads together,” said Peikon. The company’s system pinpoints genes involved in neurodegeneration and interrogates how they affect the biology of disease using cell-based screens and animal models. Methods of interrogation include sequencing active genes in cells and imaging techniques such as 3D microscopy of mouse brains. Zoghbi’s lab provides expertise in large-scale screens and animal studies . Zador’s lab licensed tech to Cajal that maps how neurons connect to each other using a method that labels and analyzes their projections using a sequencing-based technique . In addition to exploring molecules that affect neurons, the company also focuses on support cells often ignored by other researchers. The company spent its first years building up a toolset for its target discovery platform. More recently, its researchers have identified molecular processes that “we are really excited about,” said Peikon. The company is now developing its drug discovery arm, focused on finding compounds that interact with their identified targets and affect their activity. The team tapped into a talented pool of employees in Seattle, including experts in functional genomics and neuroscience. Dervan pointed to the deep biotech talent pool in the region, home to the University of Washington and the Allen Institute for Brain Science. “That was the nucleating force, the gravitational pull that brought us to Seattle,” said Dervan. The company spent its early days at Alexandria Launch Labs, an incubator space in Seattle’s Eastlake neighborhood, and is now growing in a larger space in the same Alexandria-owned building. The company will move into a nearby new Alexandria building at 1150 Eastlake in 2023. Alexandria Venture Investments participated in the funding round, along with Two Sigma Ventures, Evotec, Dolby Family Ventures and others. The company is named after Santiago Ramón y Cajal, a Spanish scientist and artist who drew the first maps showing the cellular content and connectivity of the brain in the late 1800’s. Charlotte Schubert is a GeekWire reporter and science journalist with a focus on biotech, healthcare, and life sciences. She is a Seattle native, former editor at Nature Medicine, and recovering lab rat. Follow her on Twitter at @schubertcm or reach her at charlotte@geekwire.com . Share

Kallyope Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kallyope Rank

Kallyope Frequently Asked Questions (FAQ)

  • When was Kallyope founded?

    Kallyope was founded in 2015.

  • Where is Kallyope's headquarters?

    Kallyope's headquarters is located at 430 East 29th Street, New York.

  • What is Kallyope's latest funding round?

    Kallyope's latest funding round is Series D.

  • How much did Kallyope raise?

    Kallyope raised a total of $479M.

  • Who are the investors of Kallyope?

    Investors of Kallyope include Lux Capital, Alexandria Venture Investments, The Column Group, Polaris Partners, Euclidean Capital and 14 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.